Cargando…

No-Dose Photodynamic Therapy Against Half-Dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy

INTRODUCTION: This study aimed to describe the effects of no-dose full-fluence photodynamic therapy without verteporfin (no-dose PDT) and to compare no-dose PDT with half-dose verteporfin full-fluence photodynamic therapy (HDFF PDT) for managing chronic central serous chorioretinopathy (cCSC). METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Servillo, Andrea, Sacconi, Riccardo, Zucchiatti, Ilaria, Grachova, Elena, Querques, Lea, Prascina, Francesco, Tombolini, Beatrice, Dorin, Giorgio, Mainster, Martin, Bandello, Francesco, Querques, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287588/ https://www.ncbi.nlm.nih.gov/pubmed/37289355 http://dx.doi.org/10.1007/s40123-023-00739-4

Ejemplares similares

Optical Coherence Tomography Parameters as Predictors of Treatment Response to Eplerenone in Central Serous Chorioretinopathy
por: Borrelli, Enrico, et al.
Publicado: (2019)

Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
por: Naseripour, Masood, et al.
Publicado: (2016)

Eplerenone Versus Observation in the Treatment of Acute Central Serous Chorioretinopathy: A Retrospective Controlled Study
por: Zucchiatti, Ilaria, et al.
Publicado: (2018)

Progressive resolution of exudation from perifoveal vascular anomalous complex: A possible role of diclofenac therapy?
por: Tombolini, Beatrice, et al.
Publicado: (2022)

Choroidal Rift: A New OCT Finding in Eyes with Central Serous Chorioretinopathy
por: Battista, Marco, et al.
Publicado: (2020)

Shedding Light on Photobiomodulation Therapy for Age-Related Macular Degeneration: A Narrative Review
por: Fantaguzzi, Federico, et al.
Publicado: (2023)

Subclinical Angioid Streaks with Pseudodrusen: A New Phenotype of Age-Related Macular Degeneration
por: Sacconi, Riccardo, et al.
Publicado: (2023)

Taking the right measures to control COVID-19 in ophthalmology: the experience of a tertiary eye care referral center in Italy
por: Borrelli, Enrico, et al.
Publicado: (2020)

Photoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapy
por: Ratanasukon, Mansing, et al.
Publicado: (2013)

Subthreshold laser treatment for reticular pseudodrusen secondary to age-related macular degeneration
por: Querques, Giuseppe, et al.
Publicado: (2021)

Microperimetric evaluation of chronic central serous chorioretinopathy after half-dose photodynamic therapy
por: Fujita, Kyoko, et al.
Publicado: (2012)

Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
por: Sanguansak, Thuss, et al.
Publicado: (2015)

Choroidal Structure after Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy
por: Alovisi, Camilla, et al.
Publicado: (2020)

Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy
por: Atik, Alp, et al.
Publicado: (2017)

Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy
por: van Rijssen, Thomas J., et al.
Publicado: (2020)

Choroidal hemodynamics in central serous chorioretinopathy after half-dose photodynamic therapy and the effects of smoking
por: Horiguchi, Etsuyo, et al.
Publicado: (2022)

Impact of COVID-19 on outpatient visits and intravitreal treatments in a referral retina unit: let’s be ready for a plausible “rebound effect”
por: Borrelli, Enrico, et al.
Publicado: (2020)

Half-Fluence, Half-Dose Photodynamic Therapy: Less Direct Damage but More Inflammation?
por: Desmettre, Thomas, et al.
Publicado: (2023)

Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report
por: Ng, Winnie WK, et al.
Publicado: (2011)

Changes in Choroidal Structures in Eyes with Chronic Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy
por: Kinoshita, Takamasa, et al.
Publicado: (2016)

Short-Term Choriocapillaris Changes in Patients with Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy
por: Nassisi, Marco, et al.
Publicado: (2017)

Subthreshold micropulse laser photocoagulation versus half-dose photodynamic therapy for acute central serous chorioretinopathy
por: Zeng, Miao, et al.
Publicado: (2022)

INCREASING EVIDENCE FOR THE SAFETY OF FOVEA-INVOLVING HALF-DOSE PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
por: Feenstra, Helena M. A., et al.
Publicado: (2023)

Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic
por: Borrelli, Enrico, et al.
Publicado: (2020)

The COVID-19 Pandemic Has Had Negative Effects on Baseline Clinical Presentation and Outcomes of Patients with Newly Diagnosed Treatment-Naïve Exudative AMD
por: Borrelli, Enrico, et al.
Publicado: (2021)

Photodynamic Therapy and Central Serous Chorioretinopathy
por: Siaudvytyte, Lina, et al.
Publicado: (2012)

Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
por: Alkin, Zeynep, et al.
Publicado: (2014)

Choroidal neovascularization secondary to half-dose photodynamic therapy for chronic central serous chorioretinopathy: A case report
por: Zhang, Zhengwei, et al.
Publicado: (2021)

One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy
por: Pichai, Jirarattanasopa, et al.
Publicado: (2021)

Bilateral asymptomatic macular hypopigmentation in a young woman: multimodal imaging and pathogenetic hypothesis
por: Fantaguzzi, Federico, et al.
Publicado: (2022)

Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy
por: Fujita, Kyoko, et al.
Publicado: (2020)

Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
por: Kumashiro, Shun, et al.
Publicado: (2021)

Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial
por: Breukink, Myrte B., et al.
Publicado: (2015)

Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: A case series
por: Al-Hinai, Ahmed S., et al.
Publicado: (2011)

Choroidal vascularity changes in idiopathic central serous chorioretinopathy after half-fluence photodynamic therapy
por: Ma, Dae Joong, et al.
Publicado: (2018)

3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization
por: Hu, Yu-Chen, et al.
Publicado: (2021)

Half-dose photodynamic therapy for serous non-neovascular retinal pigment epithelial detachment
por: Inoda, Satoru, et al.
Publicado: (2019)

Long-Term Effect of Half-Fluence Photodynamic Therapy on Fundus Autofluorescence in Acute Central Serous Chorioretinopathy
por: Stattin, Martin, et al.
Publicado: (2020)

Half-fluence Photodynamic Therapy for Central Serous Chorioretinopathy in a Patient Receiving Corticosteroids for Behçet’s Uveitis
por: Özdemir, Hüseyin Baran, et al.
Publicado: (2022)

The relationship between foveal outer nuclear layer thickness in the active and resolved phases of central serous chorioretinopathy treated with half-dose photodynamic therapy
por: Yu, Jia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iahp7dvdots6uqhateldo9230r